Log in

NASDAQ:SHPG - Shire Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$179.20
0.00 (0.00 %)
(As of 01/8/2019)
Today's Range
$179.20
Now: $179.20
$179.20
50-Day Range
$179.20
MA: $179.20
$179.20
52-Week Range
$123.73
Now: $179.20
$182.47
VolumeN/A
Average Volume2.21 million shs
Market Capitalization$54.71 billion
P/E Ratio11.83
Dividend Yield0.19%
Beta0.87
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SHPG
CUSIPN/A
Phone353-1609-6000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$15.16 billion
Cash Flow$22.71 per share
Book Value$119.43 per share

Profitability

Net Income$4.27 billion

Miscellaneous

EmployeesN/A
Market Cap$54.71 billion
Next Earnings DateN/A
OptionableOptionable

Receive SHPG News and Ratings via Email

Sign-up to receive the latest news and ratings for SHPG and its competitors with MarketBeat's FREE daily newsletter.


Shire (NASDAQ:SHPG) Frequently Asked Questions

What is Shire's stock symbol?

Shire trades on the NASDAQ under the ticker symbol "SHPG."

How were Shire's earnings last quarter?

Shire PLC (NASDAQ:SHPG) issued its earnings results on Thursday, April, 26th. The biopharmaceutical company reported $3.86 EPS for the quarter, beating the Zacks' consensus estimate of $3.58 by $0.28. The biopharmaceutical company earned $3.77 billion during the quarter. Shire had a return on equity of 12.70% and a net margin of 30.63%. The business's revenue was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.63 earnings per share. View Shire's Earnings History.

What price target have analysts set for SHPG?

3 Wall Street analysts have issued twelve-month price targets for Shire's shares. Their forecasts range from $222.00 to $222.00. On average, they anticipate Shire's stock price to reach $222.00 in the next year. This suggests a possible upside of 23.9% from the stock's current price. View Analyst Price Targets for Shire.

What is the consensus analysts' recommendation for Shire?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Shire in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Shire.

Has Shire been receiving favorable news coverage?

Media stories about SHPG stock have trended extremely positive recently, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Shire earned a media sentiment score of 5.0 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Shire.

Who are some of Shire's key competitors?

What other stocks do shareholders of Shire own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Shire investors own include Gilead Sciences (GILD), Celgene (CELG), Intel (INTC), Merck & Co., Inc. (MRK), Cisco Systems (CSCO), Walt Disney (DIS), Starbucks (SBUX), Johnson & Johnson (JNJ), Pfizer (PFE) and Exxon Mobil (XOM).

Who are Shire's key executives?

Shire's management team includes the folowing people:
  • Dr. Flemming Ornskov M.P.H., MBA, M.D., MPH, CEO, MD & Exec. Director (Age 60)
  • Mr. Thomas J. W. Dittrich, CFO & Director (Age 54)
  • Gisele Dion, Chief Accounting Officer
  • Mr. Matthew Walker, Head of Technical Operations (Age 54)
  • Dr. Andreas Busch Ph.D., Head of R&D and Chief Scientific Officer (Age 55)

What is Shire's stock price today?

One share of SHPG stock can currently be purchased for approximately $179.20.

How big of a company is Shire?

Shire has a market capitalization of $54.71 billion and generates $15.16 billion in revenue each year. The biopharmaceutical company earns $4.27 billion in net income (profit) each year or $15.15 on an earnings per share basis. View Additional Information About Shire.

What is Shire's official website?

The official website for Shire is http://www.shire.com/.

How can I contact Shire?

Shire's mailing address is BLOCK 2 MIESIAN PLAZA 50-58 BAGGOT STREET LOWER, Dublin L2, D02. The biopharmaceutical company can be reached via phone at 353-1609-6000 or via email at [email protected]


MarketBeat Community Rating for Shire (NASDAQ SHPG)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  1,063 (Vote Outperform)
Underperform Votes:  600 (Vote Underperform)
Total Votes:  1,663
MarketBeat's community ratings are surveys of what our community members think about Shire and other stocks. Vote "Outperform" if you believe SHPG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SHPG will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/8/2019 by MarketBeat.com Staff

Featured Article: Blockchain

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel